Screening for Primary Aldosteronism

Patient Preparation

• Patients should be potassium-replete before testing, as hypokalemia can suppress aldosterone production, and ideally, interfering medications should be substituted or discontinued when clinically appropriate, according to the American Heart Association 1, 2, 3
• Beta-blockers, centrally acting drugs, and diuretics should be stopped when feasible, and long-acting calcium channel blockers and alpha-receptor antagonists can be used as alternatives as they minimally interfere with ARR, as recommended by the American College of Cardiology 2
• If medications cannot be stopped, interpret results in the context of the specific medications the patient is taking, as suggested by the American Heart Association 2

Timing and Collection

• Collect blood in the morning, with the patient out of bed for 2 hours prior to collection and seated for 5-15 minutes immediately before collection, as recommended by the American College of Cardiology 1, 3
• Blood should be drawn with the patient in a seated position, according to the American Heart Association 2, 3

Test Interpretation

• An aldosterone/renin ratio (ARR) of 20 ng/dL per ng/mL/hr has excellent sensitivity and specificity (>90%) for confirming hyperaldosteronism, as reported by the American College of Cardiology 1
• For a positive ARR test, plasma aldosterone concentration should be at least 10-15 ng/dL in addition to the elevated ratio, as suggested by the American Heart Association 4, 2
• The specificity of the ratio improves if a minimum plasma renin activity of 0.5 ng/mL/h is used in calculations, according to the American College of Cardiology 3, 2

Confirmatory Testing

• A positive screening test requires confirmation with additional testing, such as oral sodium loading with 24-hour urine aldosterone measurement or saline suppression test, as recommended by the American College of Cardiology 1, 3, 2
• Testing should be performed with unrestricted salt intake and normal serum potassium levels, and mineralocorticoid receptor antagonists should be withdrawn at least 4 weeks before testing, as suggested by the American Heart Association 2

Prevalence

• Primary aldosteronism is present in up to 20% of individuals with resistant hypertension, as reported by the American Heart Association 3

Diagnostic Approach for Primary Aldosteronism

Introduction to Diagnostic Approach

• The American College of Cardiology recommends a diagnostic approach for primary aldosteronism that begins with screening using the plasma aldosterone-to-renin ratio (ARR) in patients with risk factors, followed by confirmatory testing, and subtype determination through imaging and adrenal venous sampling to guide appropriate treatment 5, 6

Who to Screen

• The American College of Cardiology suggests screening patients with resistant hypertension (BP not controlled on 3 medications including a diuretic) 5, 6
• The European Heart Journal recommends screening patients with severe hypertension (BP >180/110 mmHg) 6

Initial Screening Test

• The American College of Cardiology recommends using the plasma aldosterone-to-renin ratio (ARR) as the initial screening test, with a positive result defined as ARR >30 (when aldosterone is measured in ng/dL and renin activity in ng/mL/h) and plasma aldosterone concentration at least 10 ng/dL 5

Common Pitfalls to Avoid

• The European Heart Journal notes that not screening high-risk patients is a common pitfall, with only ~2-4% of eligible patients getting screened 6
• The American College of Cardiology warns against relying solely on hypokalemia as a marker, as it is absent in the majority of cases 5

Referral Considerations

• The European Heart Journal recommends referring patients with resistant hypertension to clinical centers with expertise in hypertension management 6
• The American College of Cardiology suggests referring patients with confirmed primary aldosteronism to a hypertension specialist or endocrinologist for further evaluation and treatment 5

Diagnosis and Management of Primary Hyperaldosteronism

Initial Screening and Diagnosis

• The American Urological Association recommends performing a focused history and physical examination to identify signs/symptoms of adrenal hormone excess, particularly hypertension and hypokalemia, in patients with suspected primary hyperaldosteronism 7, 8
• Patients with adrenal incidentalomas and hypertension and/or hypokalemia should be screened for primary aldosteronism using an aldosterone-to-renin ratio (ARR) 7, 8

Subtype Determination and Treatment

• The Endocrine Society recommends determining if the condition is unilateral or bilateral after biochemical confirmation, with initial imaging using non-contrast CT scan of the adrenal glands 7, 8
• Adrenal vein sampling is recommended prior to offering adrenalectomy in patients with primary aldosteronism, as up to 25% of patients might undergo unnecessary adrenalectomy based on CT findings alone 7, 8, 9
• Laparoscopic adrenalectomy is the treatment of choice for unilateral aldosterone-producing adenomas, with complete biochemical success achieved in most patients 7, 8

Special Considerations

• A multidisciplinary review by endocrinologists, surgeons, and radiologists is recommended when imaging is not consistent with a benign lesion, there is evidence of hormone hypersecretion, or the tumor has grown significantly during follow-up imaging 7
• Adrenal surgery should be considered with caution, and a multidisciplinary review is recommended before proceeding 7, 8

Primary Aldosteronism Diagnosis and Treatment

Diagnostic Testing

• The American Heart Association recommends that patients should be potassium-replete before testing, as hypokalemia can suppress aldosterone production, and ideally, interfering medications should be discontinued when clinically appropriate, with a positive result defined as ARR >30 when plasma aldosterone is measured in ng/dL and plasma renin activity in ng/mL/h, and plasma aldosterone concentration should be at least 10 ng/dL to interpret the test as positive 10
• Confirmatory testing, such as the intravenous saline suppression test, should be performed with unrestricted salt intake and normal serum potassium levels, and options include the oral salt-loading test with 24-hour urine aldosterone measurement 10

Treatment

• The American Heart Association recommends laparoscopic unilateral adrenalectomy as the treatment of choice for unilateral disease, which improves blood pressure in virtually 100% of patients and results in complete cure of hypertension in approximately 50% 10
• For bilateral disease, medical therapy with mineralocorticoid receptor antagonists (MRAs) is the cornerstone of treatment, with spironolactone as the first-line treatment, and eplerenone as an alternative option with fewer anti-androgenic side effects 10

Calculating and Interpreting Aldosterone to Renin Ratio

Formula and Calculation

• The aldosterone to renin ratio (ARR) is calculated by dividing the plasma aldosterone concentration by the plasma renin activity, with a standard cutoff value of ≥30 when using these units, as recommended by the American Heart Association 11
• ARR = Plasma Aldosterone Concentration (ng/dL) ÷ Plasma Renin Activity (ng/mL/h), with the American Journal of Kidney Diseases suggesting this formula 11, 12
• For a positive test, plasma aldosterone concentration should be at least 10 ng/dL in addition to the elevated ratio, according to the American Heart Association 11

Clinical Application and Interpretation

• ARR is the recommended screening test for primary aldosteronism in patients with resistant hypertension, hypokalemia, incidentally discovered adrenal mass, family history of early-onset hypertension, or stroke at a young age, as suggested by the American Journal of Kidney Diseases 12, 13
• Patients should have unrestricted salt intake and normal serum potassium levels before testing, as recommended by the American Heart Association 11
• If primary aldosteronism is confirmed, further evaluation with adrenal venous sampling may be needed to determine if the source is unilateral or bilateral, according to the American Heart Association 11

Diagnóstico y Manejo del Hiperaldosteronismo Primario

Población a Evaluar

• Se recomienda realizar cribado de hiperaldosteronismo primario en pacientes con hipertensión que presenten alguna de las siguientes condiciones: hipertensión resistente, hipopotasemia, masa adrenal descubierta incidentalmente, antecedentes familiares de hipertensión de inicio temprano o accidente cerebrovascular a edad temprana (<40 años), según la American Heart Association y la American Journal of Kidney Diseases 14, 15
• El hiperaldosteronismo primario está presente en hasta el 20% de los pacientes con hipertensión resistente, por lo que es fundamental su detección, según la American Journal of Kidney Diseases 15

Prueba de Cribado

• Se recomienda utilizar la relación aldosterona/renina plasmática (ARR) como prueba de cribado inicial, según la American Heart Association y la American Journal of Kidney Diseases 14, 15

Pruebas Confirmatorias

• Una prueba de cribado positiva requiere confirmación con pruebas adicionales para demostrar la secreción autónoma de aldosterona, según la American Heart Association 14
• Las opciones para pruebas confirmatorias incluyen la prueba de sobrecarga oral de sodio con medición de aldosterona en orina de 24 horas y la prueba de supresión con infusión salina intravenosa, según la American Heart Association 14

Diagnosis and Management of Primary Aldosteronism

Definition and Diagnosis

• Primary aldosteronism is defined as inappropriately high aldosterone production that is relatively autonomous and cannot be suppressed with sodium loading, distinguishing it from physiologic aldosterone secretion, according to the American Heart Association 16
• The American Heart Association recommends performing confirmatory testing after a positive screening test (ARR >30 with plasma aldosterone ≥10 ng/dL) in patients with resistant hypertension, hypokalemia, adrenal incidentaloma, or family history of early-onset hypertension 16

Management and Treatment

• The American Heart Association suggests referring patients with confirmed primary aldosteronism to a hypertension specialist or endocrinologist for subtype determination 16

Diagnostic Criteria for Primary Hyperaldosteronism

Confirmatory Testing and Subtype Differentiation

• The European Heart Journal suggests that a fludrocortisone suppression test can be used to confirm the diagnosis of primary hyperaldosteronism, where failure to reduce plasma aldosterone below threshold confirms the diagnosis, in patients with a positive aldosterone-to-renin ratio (ARR) screening test 17
• The European Heart Journal also notes that CT findings alone are insufficient for treatment decisions, as adenomas on imaging can represent hyperplasia, and false positives are common due to nodular hyperplasia, highlighting the importance of adrenal venous sampling (AVS) in differentiating unilateral from bilateral disease 17

Diagnosis and Treatment of Primary Aldosteronism

Introduction to Primary Aldosteronism

• Primary aldosteronism is present in up to 20% of individuals with resistant hypertension, according to the American Journal of Kidney Diseases 18
• The American Journal of Kidney Diseases recommends that all patients with confirmed primary aldosteronism be referred to a hypertension specialist or endocrinologist for further evaluation and treatment 18

Subtype Determination and Treatment

• Adrenal Venous Sampling (AVS) is mandatory before offering adrenalectomy to distinguish unilateral from bilateral disease, except in patients <40 years when imaging shows a single affected gland, as bilateral hyperplasia is rare in this population, as stated by the Journal of the National Comprehensive Cancer Network 19

Diagnostic Approach for Primary Aldosteronism

Screening and Diagnosis

• The American Heart Association recommends screening all patients with resistant hypertension, as primary aldosteronism is present in up to 20% of these individuals 20
• The American College of Cardiology suggests that a positive screening test is defined as Aldosterone-Renin Ratio (ARR) ≥30 and plasma aldosterone concentration ≥10 ng/dL 20
• Confirmatory testing, such as intravenous saline suppression test or oral sodium loading test, is required to demonstrate autonomous aldosterone secretion that cannot be suppressed 20
• The Endocrine Society recommends performing confirmatory testing with unrestricted salt intake and normal serum potassium levels 20

Treatment

• The American Heart Association recommends laparoscopic unilateral adrenalectomy as the treatment of choice for unilateral aldosterone production, improving blood pressure in virtually 100% of patients and curing hypertension in approximately 50% 20
• Adrenalectomy normalizes hypokalemia, lowers blood pressure, reduces antihypertensive medication requirements, and improves cardiac and kidney function parameters 20
• For bilateral adrenal hyperplasia or patients unsuitable for surgery, the American College of Cardiology suggests treating with mineralocorticoid receptor antagonists, such as spironolactone, as the cornerstone of therapy 20

Laboratory Findings in Hyperaldosteronism

Primary Screening Tests

• The American College of Cardiology recommends that elevated plasma aldosterone concentration (≥10-15 ng/dL), suppressed plasma renin activity, and an aldosterone-to-renin ratio (ARR) >30 are key laboratory findings in hyperaldosteronism, with hypokalemia present in only approximately 50% of cases 21

Electrolyte Abnormalities

• Hypokalemia is present in only 50% of patients with primary aldosteronism, and normal potassium does not exclude the diagnosis, as excessive aldosterone-induced potassium excretion in the distal renal tubule can occur 21
• Sodium retention occurs due to aldosterone's action on the distal convoluted tubule, leading to mild extracellular volume expansion, which normally suppresses renin in primary aldosteronism 21

Confirmatory Testing

• After a positive ARR, confirmatory testing is mandatory to demonstrate autonomous aldosterone secretion, and the intravenous saline suppression test involves infusing 2L of normal saline over 4 hours, with failure to suppress plasma aldosterone below 5 ng/dL after saline loading confirming the diagnosis 21
• An alternative confirmatory test involves oral salt loading with measurement of 24-hour urine aldosterone, and testing should be performed with unrestricted salt intake and normal serum potassium levels 21

Additional Laboratory Findings

• Serum creatinine may be elevated, particularly in patients with severe hypertension and secondary kidney damage, and in patients with renal impairment, the risk of hyperkalemia increases significantly when treated with mineralocorticoid receptor antagonists 21

Diagnostic Approach for Hyperaldosteronism

Introduction to Diagnostic Approach

• The American College of Cardiology recommends screening high-risk hypertensive patients using the plasma aldosterone-to-renin ratio (ARR), followed by confirmatory testing with saline suppression or oral salt loading, then proceeding to adrenal venous sampling to differentiate unilateral from bilateral disease before determining treatment 22

Who Should Be Screened

• The American College of Cardiology suggests screening for primary aldosteronism in hypertensive patients with an incidentally discovered adrenal mass on CT or MRI 22

Initial Screening Test: Aldosterone-to-Renin Ratio (ARR)

• The American College of Cardiology recommends ensuring unrestricted salt intake and normal serum potassium levels before testing 22
• The American College of Cardiology suggests that a positive screening test requires both an ARR ≥30 and a plasma aldosterone concentration ≥10-15 ng/dL 22

Confirmatory Testing

• The American College of Cardiology recommends confirming a positive ARR screening test with additional testing, such as an intravenous saline suppression test or an oral sodium loading test 22

Referral Recommendations

• The American College of Cardiology recommends referring all patients with confirmed primary aldosteronism to a hypertension specialist or endocrinologist for subtype determination and treatment planning 22

Common Diagnostic Pitfalls

• The American College of Cardiology warns against relying on hypokalemia as a screening trigger, as it is absent in 50% of primary aldosteronism cases 22
• The American College of Cardiology advises against proceeding to surgery based on CT findings alone and recommends adrenal venous sampling (AVS) to definitively distinguish unilateral from bilateral disease 22
• The American College of Cardiology recommends withdrawing mineralocorticoid receptor antagonists for at least 4 weeks before testing 22

Diagnosis and Management of Hyperaldosteronism

Patient Preparation and Screening

• The European Society of Cardiology recommends screening all patients with resistant hypertension, severe hypertension, hypokalemia, adrenal incidentaloma, family history of early-onset hypertension, or stroke at age <40 years using the aldosterone-to-renin ratio (ARR), followed by confirmatory testing if positive, then adrenal venous sampling to determine laterality before proceeding to treatment 23
• Stop beta-blockers, centrally acting drugs, and diuretics when clinically feasible, as these cause false-positive results by suppressing renin, according to the European Heart Journal 23

Confirmatory Testing and Subtype Determination

• The European Heart Journal suggests that all positive ARR screening tests require confirmatory testing to demonstrate autonomous aldosterone secretion that cannot be suppressed with sodium loading, although the specific details of this process are not provided in the cited reference 23

Treatment Algorithm

• No specific treatment guidelines are provided with associated citations, however, the initial screening and diagnosis process is well outlined by the European Heart Journal 23

Interpreting Renin and Aldosterone Labs for Primary Aldosteronism

Screening and Diagnosis

• The European Society of Cardiology recommends the aldosterone-to-renin ratio (ARR) as the screening test for primary aldosteronism, with a positive screen defined as ARR ≥30 AND plasma aldosterone ≥10 ng/dL, in patients with resistant hypertension or severe hypertension 24
• The European Heart Journal suggests that primary aldosteronism affects up to 20% of patients with resistant hypertension and up to 12% of those with severe hypertension, highlighting the importance of screening 24

Patient Preparation

• The European Heart Journal recommends testing patients on their current medications and interpreting results in context, or discontinuing interfering medications like beta-blockers, diuretics, and ACE inhibitors/ARBs when clinically feasible, to ensure accurate ARR results 24
• The European Heart Journal advises against relying solely on hypokalemia for diagnosis, as it is absent in 50% of primary aldosteronism cases, and recommends ensuring unrestricted salt intake and correct timing of blood collection for accurate interpretation 24

Interpreting Results

• The European Heart Journal states that a high ARR (≥30) with high aldosterone (≥10 ng/dL) suggests primary aldosteronism, but confirmatory testing is mandatory due to the test's limitations, with sensitivity of 22-66% and specificity of 67-99% depending on the population and medications 24
• The European Heart Journal recommends oral salt loading with 24-hour urine aldosterone measurement as a confirmatory test for primary aldosteronism 24
• The European Heart Journal suggests that mineralocorticoid receptor antagonists should be withdrawn at least 4 weeks before testing to ensure accurate results 24

Initial Screening for Primary Aldosteronism

Screening Recommendations

• The American College of Cardiology recommends ordering a simultaneous plasma aldosterone concentration and plasma renin activity to calculate the aldosterone-to-renin ratio (ARR) as the initial screening test 25
• The American College of Cardiology suggests screening patients with high-risk features, including resistant hypertension, spontaneous or substantial diuretic-induced hypokalemia, incidentally discovered adrenal mass, family history of early-onset hypertension or stroke at young age, for primary aldosteronism 25
• The American College of Cardiology recommends using an ARR ≥30 and plasma aldosterone concentration ≥10-15 ng/dL as positive screening test criteria 25
• The American College of Cardiology advises referring all patients with positive screening tests to a hypertension specialist or endocrinologist for confirmatory testing, subtype determination, and treatment planning 25

Potassium Supplementation in Primary Aldosteronism Diagnosis

Importance of Potassium Repletion

• The American College of Cardiology recommends potassium supplementation during salt challenge testing for primary aldosteronism to maintain serum potassium in the normal range, as hypokalemia can suppress aldosterone production and lead to false-negative results 26
• The American College of Cardiology guidelines state that patients should be potassium-replete before testing, as hypokalemia can suppress aldosterone production, directly affecting test accuracy 26

Practical Implementation

• Experts target the 4.0-5.0 mEq/L range to optimize test sensitivity, according to the American Heart Association 27, 28
• Correcting hypokalemia before initiating the salt challenge is crucial, as recommended by the American College of Cardiology 26

Common Pitfalls to Avoid

• Hypokalemia is absent in approximately 50% of primary aldosteronism cases, according to the American College of Cardiology 26
• Mineralocorticoid receptor antagonists must be withdrawn for at least 4 weeks before testing, and patients should be monitored for rebound hypokalemia, as recommended by the American College of Cardiology 26

Aldosterone-Renin Ratio Testing Requirements

Patient Preparation

• The American College of Cardiology recommends that the aldosterone-renin ratio (ARR) blood test should be performed in the morning after the patient has been out of bed for at least 2 hours and seated for 5-15 minutes immediately before blood collection 29
• Patients must be potassium-replete before testing because hypokalemia suppresses aldosterone production and causes false-negative results 29, 30
• The American Heart Association suggests encouraging unrestricted (liberal) salt intake before testing 30

Medication Management

• The Endocrine Society recommends that beta-blockers, centrally acting drugs, and diuretics should be discontinued when possible, and mineralocorticoid receptor antagonists (spironolactone, eplerenone) must be withdrawn at least 4 weeks before testing 30
• Long-acting calcium channel blockers (like verapamil slow-release) and alpha-receptor antagonists (prazosin, doxazosin, hydralazine) are safe alternatives to use and minimally interfere with ARR 30

Test Interpretation Thresholds

• A positive screening test requires BOTH an ARR ≥20-30 ng/dL per ng/mL/hr and a plasma aldosterone concentration ≥10-15 ng/dL 29, 30
• The American College of Cardiology recommends that specificity improves if minimum plasma renin activity of 0.5 ng/mL/h is used 29

Next Steps After Positive Screening

• The Hypertension Society recommends that all patients with positive ARR screening require confirmatory testing (intravenous saline suppression test or oral sodium loading with 24-hour urine aldosterone) to demonstrate autonomous aldosterone secretion 29, 30
• Referral to a hypertension specialist or endocrinologist is necessary for subtype determination and treatment planning 30

Screening and Diagnosis of Primary Aldosteronism

Patient Selection and Preparation

• The American College of Cardiology recommends screening for primary aldosteronism in patients with resistant hypertension, spontaneous or substantial diuretic-induced hypokalemia, incidentally discovered adrenal mass, family history of early-onset hypertension or stroke at young age, and severe hypertension 31
• Ensure potassium repletion before testing to avoid false-negative results, as hypokalemia suppresses aldosterone production 31
• Discontinue interfering medications when clinically feasible, such as beta-blockers, centrally acting drugs, and diuretics, which suppress renin and cause false-positives 31
• Withdraw mineralocorticoid receptor antagonists, such as spironolactone and eplerenone, at least 4 weeks before testing 31

Blood Collection and Interpretation

• Collect blood in the morning, preferably between 0800-1000 hours, with the patient out of bed for 2 hours prior to collection and seated for 5-15 minutes immediately before blood draw 31
• A positive screening test requires both an aldosterone-to-renin ratio (ARR) ≥20-30 and a plasma aldosterone concentration ≥10-15 ng/dL 31
• The specificity of the ARR improves if a minimum plasma renin activity of 0.5 ng/mL/h is used in calculations 31

Next Steps After Positive Screening

• All positive ARR screening tests require confirmatory testing to demonstrate autonomous aldosterone secretion, such as intravenous saline suppression test, oral sodium loading with 24-hour urine aldosterone measurement, or fludrocortisone suppression test 31
• Refer all patients with confirmed primary aldosteronism to a hypertension specialist or endocrinologist for subtype determination and treatment planning 31

Management of Elevated Aldosterone with Low ACTH

Understanding the Clinical Context

• Low ACTH with elevated aldosterone indicates autonomous aldosterone production independent of the renin-angiotensin-aldosterone system, which is the hallmark of primary aldosteronism (Conn syndrome), according to the European Heart Journal 32
• The low ACTH is expected because aldosterone excess causes volume expansion and hypertension, which suppresses the hypothalamic-pituitary-adrenal axis feedback, as reported in the Journal of Internal Medicine 33
• Ensure the patient is not taking exogenous glucocorticoids, as these can suppress ACTH and confound interpretation, as noted in the Journal of Internal Medicine 33

Determining Unilateral vs. Bilateral Disease

• This distinction is mandatory because it determines whether the patient is a surgical candidate (unilateral disease) or requires lifelong medical therapy (bilateral disease), according to the European Heart Journal 32

Treatment Based on Subtype

• For unilateral disease, laparoscopic unilateral adrenalectomy is the treatment of choice, as recommended by the European Heart Journal 32
• For bilateral disease, medical therapy with mineralocorticoid receptor antagonists (MRAs) is the cornerstone of lifelong treatment, according to the European Heart Journal 32
• The European Heart Journal recommends starting with spironolactone 50-100 mg once daily, with titration up to 300-400 mg once daily if necessary 32
• Alternative treatment with eplerenone is less potent than spironolactone and requires twice-daily administration, as noted in the European Heart Journal 32

Special Considerations

• Familial hyperaldosteronism type 1 can be corrected with low-dose dexamethasone, which is free of glucocorticoid effects and safe during pregnancy, as reported in the European Heart Journal 32
• Patients with confirmed primary aldosteronism should be referred to a hypertension specialist or endocrinologist for subtype determination and treatment planning, as recommended by the European Heart Journal 34

Post-Treatment Monitoring

• Even after successful adrenalectomy, some patients have residual hypertension due to vascular remodeling from delayed diagnosis, as noted in the European Heart Journal 32
• The rate of cure is higher when diagnosis is made early in the disease course, according to the European Heart Journal 32
• The European Heart Journal recommends ensuring adequate blood pressure control and assessing for medication side effects 32

Management of Primary Aldosteronism

Diagnosis and Confirmation

• For an adult with elevated aldosterone/renin ratio, hypertension, and hypokalemia, confirmation of autonomous aldosterone secretion with a suppression test is necessary, followed by determination of laterality with adrenal venous sampling, according to the American Heart Association 35
• Confirmatory testing, such as oral sodium loading test, is required to demonstrate autonomous aldosterone production, as recommended by the Endocrine Society 35

Treatment and Management

• Laparoscopic unilateral adrenalectomy is the treatment of choice for unilateral disease, improving blood pressure in virtually 100% of patients, as stated by the American College of Surgeons 35
• Medical therapy with mineralocorticoid receptor antagonists, such as spironolactone, is the cornerstone of lifelong treatment for bilateral disease, as recommended by the National Institutes of Health 35

Resistant Hypertension Management with Aldosterone Renin Ratio

Patient Screening and Diagnosis

• The American Heart Association recommends screening all patients with resistant hypertension using the aldosterone-to-renin ratio (ARR), and if positive (ARR ≥30 with aldosterone ≥10 ng/dL), add spironolactone 25-50 mg daily while awaiting confirmatory testing, as this provides significant blood pressure reduction regardless of whether primary aldosteronism is ultimately confirmed 36
• Primary aldosteronism is present in up to 20% of patients with resistant hypertension, making screening essential in this population 36
• Patients with severe hypertension (BP >180/110 mmHg) should be screened for primary aldosteronism 37

Treatment and Management

• The American College of Cardiology recommends starting spironolactone 25-50 mg daily immediately after positive ARR screening, even before confirmatory testing is completed, as it provides significant additional BP reduction of 25/12 mmHg when added to multidrug regimens in resistant hypertension 36, 37
• Spironolactone provides significant blood pressure reduction regardless of whether formal primary aldosteronism is confirmed, suggesting benefit in both true primary aldosteronism and aldosterone-sensitive hypertension 36
• Low doses (25-50 mg daily) of spironolactone are effective and minimize adverse effects 36, 37

Monitoring and Adverse Effects

• The American Heart Association recommends monitoring serum potassium within 1 week of spironolactone initiation and regularly thereafter, as the risk of hyperkalemia is increased in older patients, those with diabetes, CKD, or concomitant use of ACE inhibitors/ARBs/NSAIDs 36

Primary Aldosteronism Diagnosis and Management

Introduction to Primary Aldosteronism

• The American Heart Association recommends that primary aldosteronism be considered a critical condition affecting 5-10% of all hypertensive patients and up to 20% of those with resistant hypertension, making it essential for identifying a potentially curable cause of hypertension that carries significantly higher cardiovascular risk than primary hypertension 38
• Primary aldosteronism causes dramatically worse outcomes than primary hypertension at equivalent blood pressure levels, including a 3.7-fold increase in heart failure, 4.2-fold increase in stroke, 6.5-fold increase in myocardial infarction, and 12.1-fold increase in atrial fibrillation 38

Patient Screening and Selection

• The American College of Cardiology recommends screening all patients with resistant hypertension, severe hypertension, adrenal incidentaloma, early-onset hypertension or stroke at young age, and spontaneous or diuretic-induced hypokalemia for primary aldosteronism using the aldosterone-renin ratio (ARR) test 38, 39
• Patients with resistant hypertension have a prevalence of primary aldosteronism of up to 20% 38, 39

Test Performance and Interpretation

• The Endocrine Society recommends that the ARR test be performed with the patient seated for 5-15 minutes immediately before blood draw, and that blood be collected in the morning (ideally 0800-1000 hours) 38
• A positive ARR requires both an ARR ≥20-30 and a plasma aldosterone concentration ≥10-15 ng/dL 38, 39
• The specificity of the ARR test improves if a minimum plasma renin activity of 0.5 ng/mL/h is used in calculations 38

Next Steps After Positive Screening

• The American Heart Association recommends that all positive ARR screening tests require confirmatory testing to demonstrate autonomous aldosterone secretion that cannot be suppressed with sodium loading 38, 39
• Confirmatory test options include the intravenous saline suppression test, oral sodium loading test, and fludrocortisone suppression test 38, 39

Management and Treatment

• The American College of Cardiology recommends referring all patients with confirmed primary aldosteronism to a hypertension specialist or endocrinologist for subtype determination and treatment planning 38

Approach to Hypertension with Hypokalemia

Diagnostic Approach

• The European Society of Cardiology recommends screening for primary aldosteronism immediately using the aldosterone-to-renin ratio (ARR) in patients with hypertension and hypokalemia, as this combination represents a potentially curable cause of hypertension that carries dramatically higher cardiovascular risk than essential hypertension alone 40
• All patients with hypertension plus hypokalemia should undergo ARR testing, as primary aldosteronism is present in up to 20% of resistant hypertension cases and up to 12% of severe hypertension (BP >180/110 mmHg) 40
• The American Heart Association suggests that spontaneous or diuretic-induced hypokalemia is strongly suggestive of primary aldosteronism, though hypokalemia is absent in approximately 50% of confirmed cases 40

Subtype Determination and Treatment

• The National Comprehensive Cancer Network recommends obtaining non-contrast CT scan of the adrenal glands as initial imaging to identify unilateral adenoma versus bilateral hyperplasia 41
• Adrenal Venous Sampling (AVS) is mandatory before offering adrenalectomy to distinguish unilateral from bilateral disease, except in patients <40 years when imaging shows only one affected gland, as bilateral hyperplasia is rare in this population 41
• The Endocrine Society suggests that high aldosterone, low renin levels are indicative of primary aldosteronism 41

Referral and Management

• The European Society of Cardiology recommends referring all patients with resistant hypertension and confirmed primary aldosteronism to a hypertension specialist or endocrinologist for subtype determination and treatment planning 40
• The American College of Cardiology suggests that never relying on presence or absence of hypokalemia alone to screen for primary aldosteronism, as 50% of cases have normal potassium 40

Screening for Primary Aldosteronism

Indications for Screening

• The American Heart Association recommends screening all patients with resistant hypertension, as primary aldosteronism affects up to 20% of this population and represents a potentially curable cause of hypertension with dramatically higher cardiovascular risk than essential hypertension 42
• Patients with resistant hypertension, defined as blood pressure remaining >140/90 mmHg despite optimal doses of three or more antihypertensive medications including a diuretic, or requires four or more drug classes, should be screened for primary aldosteronism 43, 42
• The American College of Cardiology suggests screening patients with hypokalemia, either spontaneous or diuretic-induced, for primary aldosteronism, although hypokalemia is absent in approximately 50% of primary aldosteronism cases 42
• Patients with adrenal incidentaloma, any incidentally discovered adrenal mass on CT or MRI performed for other reasons, should be screened for primary aldosteronism 42
• The Endocrine Society recommends screening patients with a family history of early-onset hypertension or stroke at young age (<40 years) in first-degree relatives, suggesting possible familial hyperaldosteronism 42
• Young-onset hypertension, patients <30-40 years of age with hypertension, particularly without traditional risk factors like obesity or metabolic syndrome, should be screened for primary aldosteronism 43

Screening Test Methodology

• The plasma aldosterone-to-renin ratio (ARR) should be used as the screening test, with a positive screen requiring ARR ≥20-30 and plasma aldosterone concentration ≥10-15 ng/dL 42

Next Steps After Positive Screening

• All positive screening tests require confirmatory testing to demonstrate autonomous aldosterone secretion, and patients with confirmed primary aldosteronism should be referred to a hypertension specialist or endocrinologist for subtype determination via adrenal venous sampling 42

Confirming Primary Aldosteronism in Patients Taking Spironolactone

Diagnostic Considerations

• A 24-hour urinary aldosterone test cannot be reliably performed to confirm primary aldosteronism in a patient already taking spironolactone, as mineralocorticoid receptor antagonists must be withdrawn for at least 4 weeks before any confirmatory testing to avoid false results, according to the American College of Cardiology and American Heart Association guidelines 44, 45
• The American College of Cardiology recommends a minimum 4-week washout period for mineralocorticoid receptor antagonists, such as spironolactone or eplerenone, before any confirmatory testing, including oral sodium loading with 24-hour urine aldosterone measurement and intravenous saline suppression test 44, 45
• If spironolactone cannot be safely discontinued due to severe hypertension or other clinical concerns, the diagnosis of primary aldosteronism cannot be definitively confirmed with standard testing, as stated by the American College of Cardiology 44, 45

Treatment and Management

• The American College of Cardiology suggests ensuring potassium repletion before confirmatory testing, as hypokalemia suppresses aldosterone production and causes false-negative results 44
• The American Heart Association recommends performing confirmatory testing, such as oral sodium loading with 24-hour urine aldosterone or IV saline suppression, with unrestricted salt intake 44, 45

Resistant Hypertension Diagnosis and Management

Screening and Testing

• The European Society of Cardiology recommends testing for primary aldosteronism in patients with resistant hypertension, as ACE inhibitors and diuretics can increase renin levels and cause false-negative results, but testing on current medications is acceptable and should be interpreted in context of known drug effects 46
• ACE inhibitors and diuretics both increase renin levels, which lowers the aldosterone-to-renin ratio and can cause false-negative results, according to the European Heart Journal 46

Treatment and Management

• The American Heart Association suggests that adding spironolactone 25-50 mg daily to multidrug regimens in resistant hypertension can provide significant additional blood pressure reduction, regardless of whether primary aldosteronism is ultimately confirmed, and low doses are effective and minimize adverse effects, although monitoring of serum potassium is necessary due to increased hyperkalemia risk with concurrent ACEI use 46

Diagnostic Approach to Primary Aldosteronism

Confirmatory Testing and Medication Considerations

• The American Heart Association recommends confirming autonomous aldosterone production before proceeding to subtype determination, as the elevated aldosterone-renin ratio is only a screening test with low specificity due to common low-renin states from volume expansion or dietary salt, with a strength of evidence level of moderate 47, 48
• The Endocrine Society suggests that mineralocorticoid receptor antagonists, such as spironolactone and eplerenone, must be withdrawn for at least 4 weeks before any testing, as they can interfere with aldosterone-renin ratio interpretation and confirmatory testing 47
• Beta-blockers and direct renin inhibitors can suppress renin and cause false-positive aldosterone-renin ratio, while ACE inhibitors and ARBs can raise renin and cause false-negative aldosterone-renin ratio, but may increase test sensitivity if renin remains suppressed despite these medications 47, 48

Subtype Determination and Treatment

• The American College of Cardiology recommends adrenal venous sampling as the gold standard for distinguishing unilateral from bilateral aldosterone hypersecretion, with a sensitivity of 95% and specificity of 100%, as CT imaging alone is insufficient for treatment decisions and can lead to unnecessary adrenalectomy in up to 25% of patients 47, 48

Renin Activity Testing in Hypertension Workup

Patient Preparation and Medication Management

• The European Society of Cardiology recommends discontinuing beta-blockers 2-5 days before testing, as they suppress renin and cause false-positive aldosterone-to-renin ratios (ARR) 49, 50
• The American College of Cardiology suggests withdrawing ACE inhibitors and ARBs at least 2 weeks before testing, as they increase renin and cause false-negative ARR 49, 50
• The European Heart Journal advises stopping diuretics when possible, as they increase renin and lower ARR, and withdrawing mineralocorticoid receptor antagonists for at least 4 weeks before testing 49
• The European Society of Cardiology recommends using long-acting calcium channel blockers and alpha-receptor antagonists as safe alternatives during the washout period, as they minimally interfere with ARR 49

Metabolic Preparation and Blood Collection

• The European Heart Journal emphasizes the importance of potassium repletion, targeting serum potassium 4.0-5.0 mEq/L, as hypokalemia suppresses aldosterone production and causes false-negative results 49
• The American College of Cardiology recommends ensuring adequate hydration, especially if diuretics were recently used, to prevent false-negative results 50, 51
• The European Society of Cardiology suggests collecting blood in the morning between 0800-1000 hours, with the patient out of bed for at least 2 hours and seated for 5-15 minutes before collection 49, 50, 51

Test Interpretation and Next Steps

• The European Heart Journal recommends using a minimum plasma renin activity of 0.5 ng/mL/h in calculations to improve specificity 49
• The American College of Cardiology advises against relying on hypokalemia alone for diagnosis, as it is absent in approximately 50% of primary aldosteronism cases, and against testing patients on interfering medications without context 49
• The European Society of Cardiology suggests referring all patients with confirmed primary aldosteronism to a hypertension specialist or endocrinologist for subtype determination via adrenal venous sampling before treatment decisions 49

Clinical Context for Testing

• The European Heart Journal recommends screening high-risk populations, including those with resistant hypertension, severe hypertension, spontaneous or diuretic-induced hypokalemia, adrenal incidentaloma, and family history of early-onset hypertension or stroke at age <40 years, with a prevalence of primary aldosteronism ranging from 12% to 20% 49

Epidemiology, Screening Indicators, and Clinical Impact of Primary Aldosteronism

Prevalence in Hypertensive Populations

• Primary aldosteronism is present in approximately 5 %–10 % of all individuals with hypertension and in up to 20 % of patients with resistant hypertension (blood pressure uncontrolled on ≥3 antihypertensive agents)【52】.

Key Screening Indicators (High‑Risk Features)

• Hypokalemia (spontaneous or diuretic‑induced) is a traditional screening cue, yet ≈ 50 % of primary aldosteronism cases have normal potassium levels, underscoring that hypokalemia alone is insufficient for case finding【52】.
• Adrenal incidentaloma identified on imaging qualifies patients for aldosterone screening【52】.
• Family history of early‑onset hypertension or stroke before age 40 is a recognized high‑risk factor warranting screening【52】.

Relative Risk of Cardiovascular Outcomes Compared with Essential Hypertension

Patients with primary aldosteronism experience markedly higher rates of major cardiovascular events than those with similarly elevated blood pressure due to essential hypertension【52】.

Benefit of Early Diagnosis and Targeted Therapy

• Prompt identification and treatment—either unilateral adrenalectomy for surgically amenable disease or mineralocorticoid‑receptor antagonist therapy for bilateral disease—can reverse aldosterone‑mediated target‑organ damage and mitigate the excess cardiovascular risk【52】.